Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Lanzhou University

ClinicalTrials.gov lists Lanzhou University as lead sponsor of 27 trials. It has 3 active development programs and 14 approved assets.

CN Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

19 0 1996 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 18 in 2026 and about 15 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Lanzhou University: 27 lead-sponsored trials and 1 legal-entity registration.

Get the Lanzhou University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (144)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Fibrosis 10
Hypertension, Portal 10
Stomach Neoplasms 9
Liver Cirrhosis 6
Disease 5

Trials by start year as sponsor or collaborator (19)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 14
2025 14
2024 7
2023 14
2022 11
2021 19
2020 10
2019 8
2018 10
2017 12

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (3)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
FMT Protocol Inflammatory Bowel Diseases Not reported 1
Lisaftoclax Precursor Cell Lymphoblastic Leukemia-Lymphoma Not reported 1
POMALIDOMIDE Multiple Myeloma Not reported 1

Approved assets (14)

Shown in this order: max phase first.

Approved assets
Drug Trials
Felodipine add Metoprolol 1
Sucralfate Suspension 1
Felodipine add Irbesartan 1
Anlotinib 1
Esomeprazole 1

Journals published in (213)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of hepatology 21
The New England journal of medicine 13
Hepatology (Baltimore, Md.) 12
Lancet (London, England) 11
Stroke 11

Organization relationships (301)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Wuhan Union Hospital Co sponsors trial with 13
First Affiliated Hospital of Anhui Medical University Co sponsors trial with 12
Qilu Hospital of Shandong University Co sponsors trial with 10
First Affiliated Hospital of GuangXi Medical University Co sponsors trial with 10
The First Hospital of Jilin University Co sponsors trial with 10

Latest dated events (135)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-09-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-08 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-26 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (82)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ADAM8 Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
BCL2 Trial sponsor Named in trial inclusion criteria
BCL6 Trial sponsor Named in trial inclusion criteria
CD79A Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (221)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CRP 12
IL6 7
TNF 7
INS 6
SLC17A5 6

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.